BridgeBio bags Alexion's ultra-rare disease asset; Allergan touts a new set of late-stage data for oral CGRP drug
→ Startup factory BridgeBio has snatched an asset from Alexion, set it up under a new company called Origin Biosciences, and funded its operations. The tech is a synthetic enzyme co-factor called cyclic pyranopterin monophosphate, or cPMP. Back when it was on Alexion’s shelves, it was dubbed ALXN1101. The therapy, which scored breakthrough therapy designation in 2013, is meant to treat patients with an ultra-rare disease caused by molybdenum cofactor deficiency (MoCD) Type A. And when they say ultra-rare, they mean it — as of 2010, there had been only 150 cases reported. This is the first ultra-rare disease deal done by BridgeBio.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
